Sign up for our FREE GI E-Weekly for more coverage like this sent to your inbox!
The new treatment is designed to be less invasive than the current interferon therapy. Instead of a 24 to 48 week course of injections, the new treatment is being administered as oral polymerase and protease inhibitors taken over a 12 week period.
The new treatment has thus far shown a 95 percent cure rate, 15 percent better than the interferon therapy cure rate.
More Articles on Gastroenterology:
LA Peer Health System Hosts Review of Barrett’s Esophagus Articles
Huntington Hospital Appoints Dr. David Rivadeneira Surgical Services Director
Dr. Harold Kaplan Teaches at Quinnipac University Medical School
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
